Company Overview
Dyadic International, Inc. operates as a biotechnology platform company focused on the development, production, and sale of industrial enzymes and other proteins for markets in the United States and internationally. The firm leverages its proprietary C1 platform specifically for pharmaceutical applications, which includes the complex development and production of various pharmaceutical products. Operating within the broader Healthcare sector and the specific Biotechnology industry, the company functions as a specialized developer of biological tools rather than a diversified healthcare conglomerate. With a market capitalization of $24.73M and annual revenue of $3.09M, the company represents a micro-cap entity with a relatively small operational footprint. The limited market capitalization and modest revenue figures indicate that Dyadic is a pre-revenue or early-stage growth company that has not yet achieved the scale necessary for profitability or significant market dominance.
Financial Health
The company reported revenue of $3.09M over the trailing twelve months, yet recorded a net income of $-7,364,628, creating a substantial gap between top-line performance and bottom-line results that reveals a highly aggressive cost structure or significant one-time expenses eroding profits. This negative net income is further compounded by negative free cash flow of $-5,454,874, which indicates that the company is burning through cash reserves to fund its operations and research initiatives rather than generating liquidity. The gross margin stands at 24.9%, suggesting that the cost of goods sold consumes the majority of revenue before operating expenses are deducted. In contrast, the operating margin is significantly worse at -269.6%, and the profit margin is -238.3%, both of which indicate that operating expenses are far exceeding revenue generation, a common characteristic of biotechnology firms in the development phase. On the balance sheet, the company holds $7.32M in cash against $5.06M in debt, resulting in a debt-to-equity ratio of 410.63, which suggests a leveraged financial position where equity is a small base supporting a larger debt load. Despite the high debt-to-equity ratio, the current ratio of 2.68 indicates that the company maintains sufficient liquid assets to cover its short-term liabilities with a comfortable buffer. The return on equity is -397.8% and the return on assets is -44.9%, metrics that reveal management has not yet been effective in generating positive returns on the capital invested in the company.
Valuation Assessment
The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -2.12, a valuation metric that implies the market is pricing in future earnings recovery rather than current profitability. The price-to-book ratio is 19.96, which indicates that the market is valuing the company at nearly 20 times its book value, suggesting a significant premium assigned to the company's intellectual property and potential future value despite current losses. The price-to-sales ratio is 8.00, and the EV/EBITDA is not applicable, metrics that suggest the valuation is heavily reliant on revenue multiples rather than earnings power, typical for speculative biotechnology assets. The stock has traded between a 52-week high of $1.45 and a 52-week low of $0.66, providing a range of volatility within which the current price fluctuates based on market sentiment and sector trends. The beta value is not available, which limits the ability to quantify the stock's price volatility relative to the broader market index based on historical data provided.
Growth & Income
Revenue growth year-over-year is -30.8%, while earnings growth is not applicable due to the company's negative earnings position, indicating that the company is currently contracting in terms of sales rather than expanding its top line. Since the company is not a dividend payer, the dividend yield is not applicable and the payout ratio is 0.0%, meaning the firm reinvests all available resources into research and development rather than distributing income to shareholders. The absence of a dividend yield confirms that Dyadic follows a growth-oriented strategy where capital is retained to fund the C1 platform and enzyme production capabilities rather than providing regular income to investors. The overall growth and income profile reflects a high-risk, high-reward biotechnology stock that offers no current income but presents significant downside risk given the recent decline in revenue and negative cash flow trajectory.